Profile
TCGX is a healthcare investment firm with headquarters and offices in Palo Alto, San Francisco, and New York City. The firm was founded by Dr. Chen Yu, who has a vision to leverage scientific breakthroughs to develop new medicines. TCGX differentiates itself by focusing on biotechnology companies and bringing a robust global network to support entrepreneurs. With a dedicated team that includes Dandan Dong, the managing partner in Asia, TCGX aims to expand its footprint in the vibrant biotech sector of the region.
TCGX invests in biotechnology, with a focus on life sciences and Healthcare Services. The firm targets investments across all stages of development, from early-stage drug discovery to late-stage companies, primarily in the US, Europe, and expanding into Asia with their new fund. The check sizes are typically in the range of $10-50 m. They manage significant assets including their flagship funds in the US and Europe, and their newly launched Asia-focused fund with $600 million committed.
Some of the notable companies that TCGX has supported include life sciences startups in North America and Europe. While specific firms were not disclosed in the available details, the firm is recognized for partnering with innovative biotechnology companies that are led by entrepreneurs aiming to develop transformative medicines for global markets.
Industry
TCGX Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
TCGX Asia Life Sciences Fund I
|
Venture Capital (VC)
|
Biotechnology
Life Sciences
|
Pre-seed
Seed
Series A
Series B
Late Stage (Series C+)
|
Asia
|
$10-50 m
|
$600 M
|
October 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.